About InVivoMAb anti-human CD19
The 4G7 monoclonal antibody reacts with human CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. CD19 contains two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signaling in conjunction with CD21 and CD81. CD19 is highly expressed in most lymphomas and leukemias including some early B-cell malignancies that do not express CD20. For these reasons CD19 is quickly becoming an attractive alternative target for the immunotherapy of lymphoproliferative disorders.
InVivoMAb anti-human CD19 Specifications
| Isotype | Mouse IgG1 |
| Recommended Isotype Control(s) | InVivoMAb mouse IgG1 isotype control, unknown specificity(BE0083) |
| Recommended InVivoPure Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer(IP0070) |
| Immunogen | Human chronic lymphocytic leukemia (CLL) cells |
| Reported Applications |
|
| Endotoxin |
|
| Purity |
|
| Formulation |
|
| Sterility | 0.2 μM filtered |
| Production | Purified from tissue culture supernatant in an animal free facility |
| Purification | Protein G |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| RRID | AB_2687804 |
| Molecular Weight | 150 kDa |
